Drug Profile
NaQuinate - Haoma Medica
Alternative Names: NaQ; OsteopuraLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Haoma Medica
- Class Small molecules
- Mechanism of Action Bone development stimulants; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic bone diseases; Osteoporosis
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for phase-I development in Metabolic bone diseases(In volunteers) in United Kingdom (PO)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Osteoporosis(In volunteers) in United Kingdom (PO)
- 26 Nov 2020 Adverse events data from a phase I trial (In volunteers) in Osteoporosis and Metabolic bone diseases released by Haoma Medica